Organovo Holdings, Inc., a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, have recently declared a publication in the scientific journal, Toxicological Sciences, which demonstrates the power of Organovo’s ExViveTM Human Liver Tissue to effectively model drug-induced liver injury leading to fibrosis.
Using Organovo’s 3D bioprinted human liver tissues, researchers from Organovo, The Institute for Drug Safety Sciences and the University of North Carolina at Chapel Hill were able to reconstruct key aspects of methotrexate and thioacetamide-induced progressive human liver injury in a way that other models have not been able to achieve. The Company’s 3D bioprinting technology creates tissues that are spatially patterned, three-dimensional, and multicellular. Organovo’s 3D bioprinted human liver tissues are composed of patient-derived parenchymal (hepatocyte) and non-parenchymal (endothelial and hepatic stellate) cell populations and can provide insights into the dynamic and complex intercellular interactions that occur during drug-induced liver injury. The ExVive platform stands out as an exceptional tool to model and understand tissue-level toxicity, owing to its durable nature and the presence of multiple tissue-specific cell types that are essential in modulating tissue injury, resistance to injury and recovery.